Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Ibrutinib Imbruvica 140 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2014 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
NA Imatinib mesylate Gleevec 400 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
NA Abemaciclib Verzenio 150 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
NA Cyclosporine Sandimmune 25mg, 50mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1983 In Use
NA Acalabrutinib Calquence 100 mg Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Yes 2017 In Use
NA Lapatinib Tykerb 250 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2007 In Use
N/A Calcium folinate Lederle Leucovorin 5mg Ancillary Therapy Chemoprotective Antidote Yes 2025 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.